Literature DB >> 14627986

Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing.

Ryan J Whitmarsh1, Charles Saginario, Ya Zhuo, Eva Hilgenfeld, Eric F Rappaport, Maureen D Megonigal, Martin Carroll, Mingli Liu, Neil Osheroff, Nai-Kong V Cheung, Diana J Slater, Thomas Ried, Turid Knutsen, Ian A Blair, Carolyn A Felix.   

Abstract

Few t(9;11) translocations in DNA topoisomerase II inhibitor-related leukemias have been studied in detail and the DNA damage mechanism remains controversial. We characterized the der(11) and der(9) genomic breakpoint junctions in a case of AML following etoposide and doxorubicin. Etoposide-, etoposide metabolite- and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal homologues of the MLL and AF-9 breakpoint sequences using an in vitro assay. Induction of DNA topoisomerase II cleavage complexes in CEM and K562 cell lines was investigated using an in vivo complex of enzyme assay. The translocation occurred between identical 5'-TATTA-3' sequences in MLL intron 8 and AF-9 intron 5 without the gain or loss of bases. The 5'-TATTA-3' sequences were reciprocally cleaved by DNA topoisomerase II in the presence of etoposide, etoposide catechol or etoposide quinone, creating homologous 4-base 5' overhangs that would anneal to form both breakpoint junctions without any processing. der(11) and der(4) translocation breakpoints in a treatment-related ALL at the same site in MLL are consistent with a damage hotspot. Etoposide and both etoposide metabolites induced DNA topoisomerase II cleavage complexes in the hematopoietic cell lines. These results favor the model in which the chromosomal breakage leading to MLL translocations in DNA topoisomerase II inhibitor-related leukemias is a consequence of DNA topoisomerase II cleavage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627986     DOI: 10.1038/sj.onc.1207052

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

Review 1.  Chromosomal translocations involving the MLL gene: molecular mechanisms.

Authors:  Peter D Aplan
Journal:  DNA Repair (Amst)       Date:  2006-06-21

2.  From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML.

Authors:  M Krumbholz; J Bradtke; D Stachel; O Peters; B Hero; W Holter; R Slany; M Metzler
Journal:  Bone Marrow Transplant       Date:  2015-07-06       Impact factor: 5.483

3.  Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons.

Authors:  Adam C Ketron; Neil Osheroff
Journal:  Phytochem Rev       Date:  2014-03-01       Impact factor: 5.374

Review 4.  Causes of oncogenic chromosomal translocation.

Authors:  Peter D Aplan
Journal:  Trends Genet       Date:  2005-10-28       Impact factor: 11.639

5.  A case of lenalidomide-dependent myelodysplastic syndrome.

Authors:  Ira J Miller; Wei-Tong Hsu; James Weisberger; Parameswaran Venugopal
Journal:  Blood Adv       Date:  2017-06-30

6.  Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity.

Authors:  Ian G Cowell; Zbyslaw Sondka; Kayleigh Smith; Ka Cheong Lee; Catriona M Manville; Malgorzata Sidorczuk-Lesthuruge; Holly Ashlene Rance; Kay Padget; Graham Hunter Jackson; Noritaka Adachi; Caroline A Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

7.  Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspot.

Authors:  Marc-Edouard Mirault; Patrick Boucher; Alain Tremblay
Journal:  Am J Hum Genet       Date:  2006-09-12       Impact factor: 11.025

Review 8.  Molecular biology of therapy-related leukaemias.

Authors:  Melanie Joannides; David Grimwade
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

9.  Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding.

Authors:  Hongan Le; Sheetal Singh; Shyh-Jen Shih; Nga Du; Sabine Schnyder; Grace A Loredo; Christine Bien; Laura Michaelis; Amir Toor; Manuel O Diaz; Andrew T Vaughan
Journal:  Genes Chromosomes Cancer       Date:  2009-09       Impact factor: 5.006

Review 10.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.